Biohaven Pharmaceutical Company acquires an option to license an anti-metallothionein antibody from Michael Lynes for the treatment of inflammatory and autoimmune diseases.

This investment will develop the potential therapeutic applications that Dr. Lynes, his MCB lab group, and collaborators at the University of Gent and Joslin Diabetes Center have been working to elucidate.